Quince Therapeutics, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 45/100
What the filing says
Quince Therapeutics approved a 20-for-1 reverse stock split effective June 29, 2026, combining 20 shares of common stock into 1 share. Concurrently, stockholders approved the 2026 Equity Incentive Plan (821,872 shares plus 1,377,845 returning shares, with 5% annual increases through 2036) and the 2026 Employee Stock Purchase Plan (142,045 shares plus 1% annual increases through 2036). No counterparties, specific dollar amounts, or dates beyond the effective time of 11:59 p.m. ET on June 29, 2026, are named.
Why this rating
Reverse split is a routine capitalization adjustment; typical for small-cap struggling firms (~$64M market cap). Equity plan reserves are moderate relative to company size; standard housekeeping documents.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.